PDCD1 and non-small cell lung carcinoma: Many additional clinical trials of PD-1/PD-L1 antibodies are also ongoing such as KEYNOTE-042 which intend to compare pembrolizumab as first-line therapy against platinum doublet chemotherapy for advanced NSCLC [22–24].